• Reduction in dysmenorrhea |
• Reduction in pelvic pain related to endometriosis |
• Reduction of menorrhagia, with improvement in iron deficiency anemia related to blood loss |
• Reduction in risk of ectopic pregnancy |
• Reduction in symptoms associated with premenstrual syndrome and premenstrual dysphoric disorder |
• Reduction in risk of benign breast disease |
• Reduction in development of new ovarian cysts (true for higher dose estrogen pills only, which suppress ovulation), but no effect on existing ovarian cysts |
• Reduction in ovarian cancer, including some hereditary forms, such as those associated with mutations in the BRCA1 or BRCA2 gene, presumably due to inhibition of ovarian stimulation |
• Reduction in endometrial cancer, due to the progestin effect |
• Reduction in colorectal cancer in current users |
• Reduction in moderate acne |
• Reduction in hirsutism |
• More regular menstrual cycles |
Do you want to add Medilib to your home screen?